Porphyrin derivates and their use as photosensitizers in photodynamic therapy

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a new class of porphyrin derivatives specifically designed to be highly effective photosensitizers for photodynamic therapy (PDT). These compounds feature substituted phenyl groups in specific positions of the porphyrin ring, resulting in superior photophysical properties such as high singlet oxygen quantum yield and stability under physiological conditions. The invention enables more efficient and targeted destruction of unwanted or malignant tissue when the compounds are activated by light at suitable wavelengths.

Use CasesContent extracted from patent full text and abstract with AI.

• Photodynamic therapy for various types of cancer, including breast, skin, lung, bladder, esophageal, gastric, uterine, ovarian, pancreatic, liver, prostate, and blood cancers.
• Treatment of dermatological disorders such as psoriasis.
• Treatment of ophthalmological conditions including age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization.
• Therapy for cardiovascular disorders such as restenosis and atherosclerotic plaques.
• Therapy for urological disorders (e.g., treatment of condyloma virus).
• Targeting and treatment of bacterial and viral infections, including infections with E. coli, Candida, Streptococcus, and Herpes simplex.
• Topical applications for skin cancers or lesions.
• Development of pharmaceutical compositions for intravenous, oral, subcutaneous, or topical administration of the new photosensitizers.

BenefitsContent extracted from patent full text and abstract with AI.

• High singlet oxygen quantum yield (~90%), resulting in more effective destruction of target cells or tissues.
• Absorption at wavelengths (680–700 nm) away from hemoglobin absorption maxima, allowing deeper tissue penetration and more selective activation.
• Excellent stability under physiological conditions, reducing unwanted degradation of the photosensitizer.
• Chemical modularity and solubility tunability, allowing adaptation for various medical and pharmaceutical uses.
• Facilitates targeted delivery by conjugation to biological carriers such as antibodies, lipids, or dendrimers, enhancing selective accumulation in diseased tissue.
• Lower dark toxicity, improving patient safety as compounds are not toxic without light activation.
• Readily synthesized through straightforward chemical methods.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to novel porphyrin derivates of formula I, especially to porphyrins which carry substituted phenyl moieties in mesoposition. The porphyrin derivates of the invention are useful as photosensitizers in photodynamic therapy (PDT), especially in photodynamic tumor therapy. Due to their excellent photophysical properties the compounds of formula I are extremely efficient in photodynamic treatment.